Physician profile
Nicholas Katcher
NPI 1497283329
$304.25
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.26 · 2021: $236 · 2022: $11.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.65 | 2021 | |
| Pfizer INC. | $62.74 | 2020-2021 | |
| Astellas Pharma US INC | $43.34 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.41 | 2021 | |
| Lilly USA, LLC | $25.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $16.06 | 2021 | |
| Amgen INC. | $14.41 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Katcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.